{"id":28964,"date":"2024-07-31T18:36:21","date_gmt":"2024-07-31T13:06:21","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28964"},"modified":"2024-08-01T10:46:02","modified_gmt":"2024-08-01T05:16:02","slug":"top-15-indications-for-oncolytic-virus-therapy","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy","title":{"rendered":"15 Prominent Indications for Oncolytic Virus Therapy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f5b958dc2e9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f5b958dc2e9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Marketed_Oncolytic_Virus_Therapies\" >Marketed Oncolytic Virus Therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#15_Notable_Indications_for_Oncolytic_Virus_Therapy\" >15 Notable Indications for Oncolytic Virus Therapy<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Melanoma\" >Melanoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Colorectal_Cancer\" >Colorectal Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Brain_Cancer\" >Brain Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Breast_Cancer\" >Breast Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Pancreatic_Cancer\" >Pancreatic Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Lung_Cancer\" >Lung Cancer&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Ovarian_Cancer\" >Ovarian Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Head_and_Neck_Cancer\" >Head and Neck Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Prostate_Cancer\" >Prostate Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Bladder_Cancer\" >Bladder Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Renal_Cell_Carcinoma\" >Renal Cell Carcinoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Hepatocellular_Carcinoma\" >Hepatocellular Carcinoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Gastric_Cancer\" >Gastric Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Soft_Tissue_Sarcoma\" >Soft Tissue Sarcoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Bone_Cancer\" >Bone Cancer<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>As cancer continues to be a leading cause of mortality worldwide, there is a growing urgency to develop innovative oncolytic virus therapies that can effectively target and eradicate cancer cells. With its unique ability to selectively infect and replicate within tumor cells, oncolytic virus therapy has emerged as a promising avenue in cancer treatment. Key factors driving <a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-cancer-therapy-market\">oncolytic virus treatment market growth<\/a> include increasing research and development activities, growing investments from pharmaceutical companies, and expanding oncolytic virus clinical trial pipelines.<\/p>\n\n\n\n<p>With ongoing advancements and strategic collaborations, oncolytic virus therapy is positioned to play a pivotal role in the future of oncology, providing patients with new hope and facilitating the development of more effective and personalized cancer therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-marketed-oncolytic-virus-therapies\"><span class=\"ez-toc-section\" id=\"Marketed_Oncolytic_Virus_Therapies\"><\/span><strong>Marketed Oncolytic Virus Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>At present, there are only three <a href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-virus-cancer-therapy\">approved oncolytic virus therapies<\/a>: <strong>Oncorine <\/strong>(Shanghai Sunway Biotech), <strong>IMLYGIC <\/strong>(Talimogene laherparepvec\/T-VEC, Amgen), and <strong>DELYTACT <\/strong>(teserpaturev\/G47\u2206, Daiichi Sankyo). Among these three, there is only one FDA-approved oncolytic virus therapy, IMLYGIC. In 2015, the FDA approved <strong>IMLYGIC <\/strong>oncolytic virus therapy by <strong>Amgen<\/strong>, the first oncolytic virus, for the local treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions in patients whose cancer had recurred after initial surgery.&nbsp;<\/p>\n\n\n\n<p>Later that year, in December, the European Commission also approved for its use in adults with unresectable melanoma that is either regionally or distantly metastatic (Stage IIIB, IIIC, and IVM1a), provided there is no involvement of bone, brain, lung, or other visceral organs. IMLYGIC is a genetically modified herpes simplex virus type 1 engineered to replicate within tumors and produce an immunostimulatory protein called granulocyte-macrophage colony-stimulating factor (GM-CSF).<\/p>\n\n\n\n<p><strong>DELYTACT <\/strong>oncolytic virus therapy is a genetically engineered herpes simplex virus type 1 (HSV-1) with three mutations designed to replicate exclusively in cancer cells. In 2021, it was granted conditional and time-limited approval by the Japan Ministry of Health, Labour and Welfare (MHLW) for use exclusively in hospitals participating as trial sites for treating malignant glioma, valid for 7 years.&nbsp;<\/p>\n\n\n\n<p>This approval was based on results from a single-arm Phase II trial demonstrating that DELYTACT increased one-year survival rates in patients with residual or recurrent glioblastoma, who had previously undergone radiotherapy and temozolomide chemotherapy. It is the first oncolytic virus therapy approved globally for brain cancer and the third oncolytic virus therapy available to patients worldwide.<\/p>\n\n\n\n<p><strong>Oncorine <\/strong>oncolytic virus therapy is a genetically engineered adenovirus known as H101 (E1B-deletion), developed by <strong>Shanghai Sunway Biotech<\/strong> in China. It is used alongside chemotherapy to treat nasopharyngeal carcinoma and head and neck cancers. The approval and effective use of Oncorine have significantly advanced the <a href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\">field of oncolytic virus immunotherapy<\/a> using oncolytic viruses.&nbsp;<\/p>\n\n\n\n<p>Also called Recombinant Human Adenovirus Type 5 Injection, Oncorine was the first oncolytic virus cancer therapy approved by the CFDA for oncolytic viruses in cancer treatment in November 2005. Since its introduction, Oncorine has demonstrated a favorable safety profile and notable anti-tumor effectiveness against various tumors and malignant pleural effusion. It has also been explored in clinical research for treating liver malignancies, pancreatic cancer, cervical cancer, malignant melanoma, and metastatic liver cancer.<\/p>\n\n\n\n<p>Additionally, oncolytic virus cancer therapy is currently only approved for melanoma and malignant glioma (in Japan). Nonetheless, the pipeline for oncolytic virus therapies indicates its potential to become a treatment option for a range of cancers, such as ovarian cancer, non-small cell lung cancer, breast cancer, and renal cell carcinoma, among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-15-notable-indications-for-oncolytic-virus-therapy\"><span class=\"ez-toc-section\" id=\"15_Notable_Indications_for_Oncolytic_Virus_Therapy\"><\/span><strong>15 Notable Indications for Oncolytic Virus Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Oncolytic virus therapy is an emerging and promising field in oncology that utilizes genetically modified viruses to selectively infect and kill cancer cells while sparing normal tissue. This innovative approach leverages the natural ability of viruses to infect cells and introduces genetic modifications to enhance their ability to target tumors.&nbsp;<\/p>\n\n\n\n<p>The development pipeline for oncolytic virus treatment is strong, with leading oncolytic virus manufacturers actively working to improve the cancer therapeutic segment. Various <a href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-virus-cancer-therapy\">types of oncolytic viruses<\/a> such as Adenovirus oncolytic virus, Herpes Simplex Virus, Vaccinia Virus, and others are under investigation for cancer therapy. Each type has distinct mechanisms of action and therapeutic possibilities, presenting a promising opportunity for novel cancer treatments.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"921\" height=\"1024\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104500\/Competitive-Analysis-of-Oncolytic-Virus-Therapy-by-Types-921x1024.png\" alt=\"Competitive Analysis of Oncolytic Virus Therapy by Types\" class=\"wp-image-28979\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104500\/Competitive-Analysis-of-Oncolytic-Virus-Therapy-by-Types-921x1024.png 921w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104500\/Competitive-Analysis-of-Oncolytic-Virus-Therapy-by-Types-270x300.png 270w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104500\/Competitive-Analysis-of-Oncolytic-Virus-Therapy-by-Types-135x150.png 135w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104500\/Competitive-Analysis-of-Oncolytic-Virus-Therapy-by-Types-768x854.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104500\/Competitive-Analysis-of-Oncolytic-Virus-Therapy-by-Types-1381x1536.png 1381w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104500\/Competitive-Analysis-of-Oncolytic-Virus-Therapy-by-Types-1841x2048.png 1841w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104500\/Competitive-Analysis-of-Oncolytic-Virus-Therapy-by-Types-1568x1744.png 1568w\" sizes=\"(max-width: 921px) 100vw, 921px\" \/><\/figure>\n\n\n\n<p>Here are 15 key indications for oncolytic virus therapy based on the number of products in the pipeline, reflecting its potential and versatility in treating various cancer types.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-melanoma\"><span class=\"ez-toc-section\" id=\"Melanoma\"><\/span><strong>Melanoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Melanoma of the skin represents<strong> 5.6%<\/strong> of all new cancer cases in the U.S. According to the American Cancer Society, if melanoma has spread to other, distant parts of the body, the survival rate is lower, about 27%. Approximately <strong>4%<\/strong> of cases are diagnosed at this stage.&nbsp;<\/p>\n\n\n\n<p>As per DelveInsight analysis, among the 7MM, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/melanoma-market\">highest cases of invasive melanoma<\/a> were observed in the US, which was <strong>~100,000<\/strong> in 2023. Melanoma is slightly more common in men than women with <strong>~60%<\/strong> of cases in men in the US.<\/p>\n\n\n\n<p>The treatment of melanoma focuses on prolonging survival, eliminating cancer, shrinking or stopping the growth of known metastases, and controlling symptomatic or risky sites of disease, thereby providing comfort. The treatment landscape of melanoma comprises immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy.&nbsp;<\/p>\n\n\n\n<p>However, surgery is also considered an option in some instances. In February 2024, the FDA approved the first TIL therapy i.e. <strong>AMTAGVI<\/strong>, developed by <strong>Iovance Biotherapeutics<\/strong>. The other approved therapies include <strong>KEYTRUDA <\/strong>(Merck) and <strong>TECENTRIQ + COTELLIC + ZELBORAF<\/strong> (Genentech).<\/p>\n\n\n\n<p>Although there are already numerous treatment options available for melanoma today, ongoing research is actively exploring even more innovative approaches. Several melanoma oncolytic virus therapies are currently being investigated at different stages of development.&nbsp;<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/melanoma-pipeline-insight\">melanoma oncolytic virus therapies in the pipeline<\/a> include <strong>Lokon Pharma\u2019s<\/strong> <strong>LOAd 703<\/strong> (Phase II), <strong>GeneMedicine\u2019s<\/strong> <strong>GM 103<\/strong> (Phase I\/II), <strong>Valo Therapeutics\u2019<\/strong> <strong>PeptiCRAd-1<\/strong> (Phase ), <strong>TILT Biotherapeutics\u2019<\/strong> <strong>TILT-123<\/strong> (Phase I), <strong>Replimune\u2019s<\/strong> <strong>RP1<\/strong> (Phase III), <strong>Replimune\u2019s<\/strong> <strong>RP2 <\/strong>(Phase I), <strong>Immvira Pharma\u2019s<\/strong> <strong>MVR-T3011<\/strong> (Phase II), <strong>Takara Bio\u2019s<\/strong> <strong>Canerpaturev <\/strong>(Phase II), <strong>SillaJen\u2019s<\/strong> <strong>PEXA-VEC <\/strong>(Phase II), <strong>BioInvent International\/Transgene\u2019s<\/strong> <strong>BT 001<\/strong> (Phase I\/II), <strong>Vyriad\u2019s Voyager-V1<\/strong> (Phase II), <strong>Istari Oncology\u2019s<\/strong> <strong>Lerapolturev <\/strong>(Phase II), <strong>Nouscom\u2019s NOUS-PEV<\/strong> (Phase I), <strong>Hangzhou Converd Co., Ltd.\u2019s<\/strong> <strong>CVD 1301.H03<\/strong> (Preclinical), <strong>Theolytics\u2019 THEO310 <\/strong>(Preclinical), and <strong>PrimeVax Immuno-Oncology PV001 DV<\/strong> (Preclinical).&nbsp;<\/p>\n\n\n\n<p>Emerging melanoma oncolytic virus therapies offer a groundbreaking approach to melanoma treatment by selectively targeting and killing cancer cells while sparing healthy tissue. These therapies not only enhance local tumor destruction but also stimulate a broader immune response against melanoma, potentially improving overall treatment outcomes and reducing the reliance on traditional therapies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-colorectal-cancer\"><span class=\"ez-toc-section\" id=\"Colorectal_Cancer\"><\/span><strong>Colorectal Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Globally, colorectal cancer is the third most commonly diagnosed cancer in males and the second in females, with <strong>1.9 million<\/strong> new cases and almost <strong>935,000<\/strong> deaths in 2020, according to the World Health Organization Global Cancer Observatory (GLOBOCAN) database. As per DelveInsight, in 2023, the<a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\"> total incident cases of colorectal cancer<\/a> were around <strong>550,000<\/strong> cases in the 7MM, which might increase by 2034.<\/p>\n\n\n\n<p>ASCO recommends that all people with mCRC who may receive an EGFR inhibitor must have their tumors tested for RAS gene mutations. If a tumor has a mutated form of the RAS gene, ASCO strongly recommends not to use EGFR inhibitors. Furthermore, the FDA now recommends that both cetuximab and panitumumab only be given to people with a tumor with non-mutated, sometimes called wild-type, RAS genes.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-pipeline-insight\">pipeline of colorectal cancer oncolytic virus therapy<\/a> is quite promising with leading companies with their candidates including <strong>Lokon Pharma\u2019s LOAd 703<\/strong> (Phase II), <strong>GeneMedicine\u2019s GM 103<\/strong> (Phase I\/II), <strong>Akamis Bio\u2019s Enadenotucirev<\/strong> (Phase I\/II), <strong>Beijing Bio-Targeting Therapeutics Technology Co., Ltd\u2019s BioTTT001<\/strong> (Phase I), <strong>Replimune\u2019s RP2<\/strong> (Phase II), <strong>Replimune\u2019s RP3 <\/strong>(Phase II), <strong>SillaJen\u2019s PEXA-VEC<\/strong> (Phase I), <strong>BioEclipse Therapeutics\u2019 CRX-100<\/strong> (Phase I), <strong>Oncolytics Biotech\u2019s Pelareorep<\/strong> (Phase II), <strong>Nouscom\u2019s NOUS-209<\/strong> (Phase I\/II),<strong> VacV Biotherapeutics VacV002<\/strong> (Preclinical), and <strong>BullFrog AI\u2019s HSV-1 oncolytic virus therapeutic<\/strong> (Discovery).&nbsp;<\/p>\n\n\n\n<p>These emerging colorectal cancer oncolytic virus therapies offer a novel approach to colorectal cancer by specifically targeting and destroying cancer cells while stimulating the immune system to fight tumors more effectively. This innovative treatment could enhance efficacy, reduce side effects, and potentially improve outcomes for patients with colorectal cancer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-brain-cancer\"><span class=\"ez-toc-section\" id=\"Brain_Cancer\"><\/span><strong>Brain Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Brain tumors account for <strong>85\u201390%<\/strong> of all primary CNS tumors. Among the 7MM, the US accounted for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/brain-cancer-market\">highest incident cases of primary brain tumors<\/a> in 2023, with around <strong>23,000<\/strong> cases; these numbers are expected to increase by 2034.<\/p>\n\n\n\n<p>Treatment options for brain cancers include surgery, radiation therapy, chemotherapy, and targeted therapy. The treatment options and recommendations depend on several factors like the size, type, and grade of the tumor, whether the tumor is putting pressure on vital parts of the brain if the tumor has spread to other parts of the CNS or the body, the possible side effects and finally, the treatment preferences and overall health of the patient.<\/p>\n\n\n\n<p>Several key players are undergoing different oncolytic virus clinical trials for brain tumors. The promising brain cancer oncolytic virus therapies include <strong>Candel Therapeutics\u2019 CAN-3110<\/strong> (Phase I), <strong>DNAtrix\u2019s DNX-2401<\/strong> (Phase II), <strong>Apices Soluciones\u2019 AloCelyvir <\/strong>(Phase I\/II), <strong>Calidi Biotherapeutics\u2019 CLD-101<\/strong> (Phase I\/II), <strong>Shanghai Yuansong Biotechnology\u2019s YSCH-01<\/strong> (Phase I), <strong>Treovir\u2019s G207<\/strong> (Phase II), <strong>Immvira Pharma\u2019s MVR-C5252<\/strong> (Phase II), <strong>Mustang Bio\u2019s MB-108 <\/strong>(Phase I), <strong>Oncolytics Biotech\u2019s Pelareorep<\/strong> (Phase II),<strong> Oryx GmbH\u2019s ParvOryx<\/strong> (Phase I), and <strong>Mustang Bio\u2019s MB-109<\/strong> (Preclinical).<\/p>\n\n\n\n<p>These upcoming brain cancer oncolytic virus therapies are expected to combat the current unmet needs faced by patients with brain tumors and add to the overall growth of the brain tumors market size.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-breast-cancer\"><span class=\"ez-toc-section\" id=\"Breast_Cancer\"><\/span><strong>Breast Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Breast cancer is one of the most common cancers worldwide and a leading cause of cancer-related deaths among women. According to the WHO, it accounts for <strong>~25%<\/strong> of all cancer cases in women. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/breast-cancer-market\">breast cancer subtype HR+\/HER2-<\/a> is the most common subtype with a total incident population of nearly <strong>476,000<\/strong> cases in the 7MM in 2023.<\/p>\n\n\n\n<p>The stage of breast cancer is an essential factor in making treatment decisions. Most women with breast cancer in Stages I, II, or III are treated with surgery, often followed by radiation therapy. Among the approved therapies, CDK4\/6 inhibitors (<strong>palbociclib, ribociclib, and abemaciclib<\/strong>) have attracted the most attention. CDK4\/6 regulates cell cycle progression by their reversible interaction with cyclin D1. Approximately <strong>29% and 14%<\/strong> of patients with HR+\/HER2- BC were found to have amplification of cyclin D1 and CDK4, respectively.<\/p>\n\n\n\n<p>The future of breast cancer treatment is looking promising. Leading <a href=\"https:\/\/www.delveinsight.com\/report-store\/breast-cancer-pipeline-insight\">breast cancer oncolytic virus therapies<\/a> in the pipeline include&nbsp; <strong>GeneMedicine\u2019s GM 103<\/strong> (Phase I\/II), <strong>Valo Therapeutics\u2019 PeptiCRAd-1<\/strong> (Phase I), <strong>Shanghai Yunying Medical Technology\u2019s R130<\/strong> (Phase I), <strong>BioEclipse Therapeutics\u2019 CRX-100<\/strong> (Phase I), <strong>Oncolytics Biotech\u2019s Pelareorep<\/strong> (Phase III),<strong> Imugene\u2019s CHECKVacc<\/strong> (Phase I), <strong>Codagenix\u2019s CodaLytic<\/strong> (Preclinical), <strong>AmunBio\u2019s AMUN-003<\/strong> (Preclinical), and <strong>PrimeVax Immuno-Oncology\u2019s PV001 DV<\/strong> (Preclinical).<\/p>\n\n\n\n<p>The launch of these breast cancer oncolytic virus therapies will not only propel the market growth but also enhance immune system responses, offering a more precise and effective approach compared to traditional methods.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pancreatic-cancer\"><span class=\"ez-toc-section\" id=\"Pancreatic_Cancer\"><\/span><strong>Pancreatic Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Pancreatic cancer is one of the most lethal cancers throughout the globe and majorly affects men compared to women. Pancreatic cancer types can be divided into two larger categories: exocrine pancreatic cancer, which includes adenocarcinoma, and neuroendocrine pancreatic cancer. The analysis from DelveInsight suggests that the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-market\">stage-specific incident cases of pancreatic cancer<\/a> in the US were maximum for distant, with nearly 50% cases, followed by regional and localized cases in 2023.<\/p>\n\n\n\n<p>The chemotherapy drugs used for the treatment of pancreatic cancer include <strong>XELODA (capecitabine), 5-FU (fluorouracil), GEMZAR (gemcitabine), CAMPTOSAR (irinotecan)<\/strong>, and others.<\/p>\n\n\n\n<p>Targeted therapies such as <strong>TARCEVA (erlotinib)<\/strong> were approved by the FDA for people with advanced pancreatic cancer in combination with the chemotherapy drug gemcitabine. Another drug, <strong>LYNPARZA (olaparib)<\/strong> is approved for people with metastatic pancreatic cancer associated with a germline (hereditary) BRCA mutation.<\/p>\n\n\n\n<p>The development <a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-pipeline-insight\">pipeline for pancreatic cancer oncolytic virus therapy<\/a> is robust, with significant involvement from key players including <strong>Candel Therapeutics\u2019 CAN-2409<\/strong> (Phase III), <strong>Theriva Biologics\u2019 VCN-01<\/strong> (Phase II), <strong>Lokon Pharma\u2019s LOAd 703<\/strong> (Phase II), <strong>Akamis Bio\u2019s NG-350A<\/strong> (Phase I), <strong>Sorrento Therapeutics\u2019 STI-1386<\/strong> (Phase I), <strong>Oncolytics Biotech\u2019s Pelareorep<\/strong> (Phase III), <strong>Oryx GmbH\u2019s ParvOryx<\/strong> (Phase II), <strong>GeneMedicine\u2019s GM102<\/strong> (Preclinical), and <strong>VacV Biotheraputics\u2019 VacV001<\/strong> (Preclinical).&nbsp;<\/p>\n\n\n\n<p>With the expected launch of these pancreatic cancer oncolytic virus therapies, the market will witness an upsurge in growth in the coming years.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-lung-cancer-nbsp\"><span class=\"ez-toc-section\" id=\"Lung_Cancer\"><\/span><strong>Lung Cancer&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>With more than<strong> 500,000 <\/strong>cases in the 7MM region, lung cancer is one of the leading causes of death worldwide. This condition is often diagnosed when the patient reaches the advanced, inoperable, or metastatic stage, adversely affecting their quality of life.<\/p>\n\n\n\n<p>According to the American Cancer Society, out of the total lung cancer cases, <strong>~80\u250085%<\/strong> of lung cancers are metastatic NSCLC. As per DelveInsight\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-non-small-cell-lung-cancer-market\">mNSCLC market report<\/a>, NSCLC is slightly more common in men than in women.&nbsp;<\/p>\n\n\n\n<p>The existing NSCLC treatment is mainly dominated by checkpoint inhibitors such as <strong>KEYTRUDA<\/strong>, and <strong>OPDIVO<\/strong>. Both KEYTRUDA and OPDIVO were introduced in 2014 and had a sizable time advantage over rival drugs. The year 2018 marked a 4-year delay in approving the third PD-1 <strong>LIBTAYO<\/strong>. As far as EGFR-positive NSCLC market size is concerned, third-generation EGFRs such as <strong>AstraZeneca\u2019s TAGRISSO<\/strong> is expected to dominate.<\/p>\n\n\n\n<p>As more targetable mutations are discovered, and new targeted drugs are developed, patients and oncologists will have an expanding array of treatment options. As a result, several companies are working with their oncolytic virus therapy treatment candidates.&nbsp;<\/p>\n\n\n\n<p>The promising lung cancer oncolytic virus therapies in the pipeline include <strong>Candel Therapeutics\u2019 CAN-2409<\/strong> (Phase II), <strong>Valo Therapeutics\u2019 PeptiCRAd-1<\/strong> (Phase I), <strong>TILT Biotherapeutics\u2019 TILT-123<\/strong> (Phase I),&nbsp; <strong>Memgen\u2019s MEM-288<\/strong> (Phase I), <strong>Transgene\u2019s TG6050<\/strong> (Phase I), <strong>Oncolytics Biotech\u2019s Pelareorep<\/strong> (Phase II), and <strong>Vyriad\u2019s Voyager-V1<\/strong> (Phase II).<\/p>\n\n\n\n<p>Approval of these <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-pipeline-insight\">lung cancer oncolytic virus therapies<\/a> will provide new and different treatment options to the patients and will hence drive the market in the coming years.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ovarian-cancer\"><span class=\"ez-toc-section\" id=\"Ovarian_Cancer\"><\/span><strong>Ovarian Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Ovarian cancer accounts for only<strong> 3%<\/strong> of cancers in women. Ovarian cancer can be malignant or cancerous, cells that affect tissues in the ovaries. According to DelveInsight\u2019s estimate, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/ovarian-cancer-market\">total diagnosed incident cases of ovarian cancer<\/a> in the 7MM comprised <strong>~57,000<\/strong> cases in 2023 and are projected to reach up to <strong>~42,000 cases<\/strong> by 2034.<\/p>\n\n\n\n<p>At present, <strong>AVASTIN <\/strong>(bevacizumab; Genentech), <strong>ZEJULA <\/strong>(niraparib; GlaxoSmithKline), <strong>RUBRACA <\/strong>(rucaparib; Clovis Oncology), <strong>LYNPARZA <\/strong>(AstraZeneca), are a few approved drug therapies for the treatment of ovarian cancer.<\/p>\n\n\n\n<p>Several treatments can be effective in ovarian cancer, but still, there are many unmet needs in terms of both efficacy and safety, with a cure for the disease being the most important unmet need in the market. To redress the existing issues, currently, many possible new treatment options are emerging from recent ovarian cancer oncolytic virus clinical trials, based both on the modifications of standard approaches and on the addition of new biological drugs to the standard treatment.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/ovarian-cancer-pipeline-insight\">ovarian cancer oncolytic virus therapy pipeline<\/a> is filled with candidates such as <strong>Lokon Pharma\u2019s LOAd 703<\/strong> (Phase II), <strong>TILT Biotherapeutics\u2019s TILT-123<\/strong> (Phase I), <strong>Genelux Corporation\u2019s Olvi-Vec<\/strong> (Phase III), <strong>BioEclipse Therapeutics\u2019 CRX-100<\/strong> (Phase I), and <strong>Oncolytics Biotech\u2019s Pelareorep <\/strong>(Phase II).<\/p>\n\n\n\n<p>The expected introduction of these emerging ovarian cancer oncolytic virus therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate are likely to boost the growth of the ovarian cancer market in the 7MM.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"618\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104548\/Oncolytic-Virus-Therapies-by-Cancer-Type-1024x618.png\" alt=\"Oncolytic Virus Therapies by Cancer Type\" class=\"wp-image-28981\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104548\/Oncolytic-Virus-Therapies-by-Cancer-Type-1024x618.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104548\/Oncolytic-Virus-Therapies-by-Cancer-Type-300x181.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104548\/Oncolytic-Virus-Therapies-by-Cancer-Type-150x90.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104548\/Oncolytic-Virus-Therapies-by-Cancer-Type-768x463.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104548\/Oncolytic-Virus-Therapies-by-Cancer-Type-1536x926.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104548\/Oncolytic-Virus-Therapies-by-Cancer-Type-2048x1235.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/01104548\/Oncolytic-Virus-Therapies-by-Cancer-Type-1568x946.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-head-and-neck-cancer\"><span class=\"ez-toc-section\" id=\"Head_and_Neck_Cancer\"><\/span><strong>Head and Neck Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Head and neck cancer refers to several types of cancers that affect the head and neck areas of the body. These cancers account for <strong>~3\u20135%<\/strong> of all cancers in the US and are common in men and people over the age of 50.<\/p>\n\n\n\n<p>HPV infection is an increasingly common risk factor for HNSCC. HPV infection is associated with most oropharyngeal cancers (<strong>&gt;70%<\/strong>) and a small minority of cancers at other anatomical sites in the head and neck. In 2023, <strong>~35%<\/strong> of <a href=\"https:\/\/www.delveinsight.com\/report-store\/head-and-neck-cancer-hnc-market\">HPV-specific incident cases of head and neck cancer<\/a> were found to be HPV-positive in the United States, as per DelveInsight estimates.<\/p>\n\n\n\n<p>Currently, no approved therapy in neo, and adjuvant settings exists, whereas the first-line therapy for R\/M-HNSCC has been revolutionized by the introduction of immune-checkpoint monoclonal antibodies inhibitors (ICIs).<\/p>\n\n\n\n<p>Key players are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their head and neck cancer oncolytic virus therapy products to improve the treatment landscape.&nbsp;<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/head-and-neck-cancer-hnc-pipeline-insight\">head and neck cancer oncolytic virus therapies<\/a> in the development pipeline include <strong>Oncolys Biopharma\u2019s OBP-301<\/strong> (Phase II), <strong>GeneMedicine\u2019s GM 103<\/strong> (Phase I\/II), <strong>TILT Biotherapeutics\u2019 TILT-123<\/strong> (Phase I), <strong>Immvira Pharma\u2019s MVR-T3011<\/strong> (Phase II), <strong>Vyriad\u2019s Voyager-V1<\/strong> (Phase II), and others.<\/p>\n\n\n\n<p>The anticipated launch of these head and neck cancer oncolytic virus therapies are poised to revolutionize HNC treatment by selectively targeting and destroying cancer cells while sparing healthy tissue. These head and neck cancer oncolytic virus therapies offer the potential for enhanced efficacy and reduced side effects compared to traditional treatments, paving the way for more personalized and effective cancer care.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-prostate-cancer\"><span class=\"ez-toc-section\" id=\"Prostate_Cancer\"><\/span><strong>Prostate Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Prostate cancer is the third most prevalent type of cancer in the US and the fourth most common worldwide. Prostate cancer is one of the most common types of cancer in men. As per DelveInsight estimates, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market-insight\">total prevalent population of prostate cancer<\/a> in the 7MM was nearly <strong>8 million<\/strong> cases in 2023.<\/p>\n\n\n\n<p>Established therapies in the metastatic prostate cancer market include <strong>Astella\/Pfizer\u2019s<\/strong> and <strong>Jansenn\u2019s<\/strong> blockbuster products <strong>XTANDI <\/strong>and <strong>ZYTIGA<\/strong>, respectively, approved for metastatic patients for over a decade now. Even though ZYTIGA\u2019s generics entered the US market in 2019, and the EU in late 2022, leading to a drastic decline in the revenue mainly in the US, the product is extensively being evaluated in combination with novel emerging therapies, leading to an increase in patient share on the compound abiraterone acetate.<\/p>\n\n\n\n<p>Several <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-pipeline-insight\">prostate cancer oncolytic virus therapies<\/a> are being investigated in different stages of development. The prostate cancer oncolytic virus therapies in the pipeline include <strong>Candel Therapeutics\u2019 CAN-2409<\/strong> (Phase III), <strong>ORCA Therapeutics\u2019 ORCA 010<\/strong> (Phase I\/II), <strong>SillaJen\u2019s PEXA-VEC<\/strong> (Phase II), and <strong>Oncolytics Biotech\u2019s Pelareorep<\/strong> (Phase II).<\/p>\n\n\n\n<p>These emerging prostate cancer oncolytic virus therapies promise to revolutionize treatment by targeting and destroying cancer cells while sparing healthy tissue, potentially offering more effective and less invasive options.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bladder-cancer\"><span class=\"ez-toc-section\" id=\"Bladder_Cancer\"><\/span><strong>Bladder Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Bladder cancer was ranked 10th among all cancers worldwide, with <strong>549,000<\/strong> new cases and <strong>200,000 <\/strong>deaths each year, accounting for <strong>3.4%<\/strong> of the global cancer burden. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/bladder-cancer-market\">prevalence of bladder cancer<\/a> is higher among males than females, as per DelveInsight.<\/p>\n\n\n\n<p>Bladder cancer treatment options depend on the stage and type of cancer and may include surgery, chemotherapy, immunotherapy, and targeted therapies. Approved drugs for bladder cancer include <strong>cisplatin, gemcitabine<\/strong>, and newer agents like <strong>nivolumab and atezolizumab<\/strong>, which are used in various combinations to manage and treat the disease.<\/p>\n\n\n\n<p>Over the past few years, the bladder cancer treatment space has heated up. Several key companies are developing <a href=\"https:\/\/www.delveinsight.com\/report-store\/bladder-cancer-pipeline-insight\">novel bladder cancer oncolytic virus therapies<\/a>. The therapies in the pipeline include <strong>CG Oncology\u2019s Cretostimogene grenadenorepvec<\/strong> (Phase III), <strong>Akamis Bio\u2019s Enadenotucirev <\/strong>(Phase I\/II), <strong>Vyriad\u2019s MV-NIS<\/strong> (Phase I), and <strong>Vaxiion Therapeutics\u2019s VAX 014<\/strong> (Phase I).<\/p>\n\n\n\n<p>The expected introduction of these emerging bladder cancer oncolytic virus therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate are likely to boost the growth of the bladder cancer market in the 7MM.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-renal-cell-carcinoma\"><span class=\"ez-toc-section\" id=\"Renal_Cell_Carcinoma\"><\/span><strong>Renal Cell Carcinoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Renal cell carcinoma is the <strong>eighth most common<\/strong> cancer in the United States, early-stage disease can often be asymptomatic, and <strong>16%<\/strong> of patients present with metastatic RCC. Renal cell carcinoma accounts for <strong>2% <\/strong>of global cancer diagnoses and deaths.&nbsp;<\/p>\n\n\n\n<p>Renal cell carcinoma is the most common type of kidney cancer. Approximately, <strong>20\u201340%<\/strong> will progress to Stage IV. As per DelveIsight analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/renal-cell-carcinoma-market\">incident cases of renal cell carcinoma<\/a> were highest in the United States among the 7MM in 2023.<\/p>\n\n\n\n<p>The treatment landscape of advanced renal cell carcinoma is governed by targeted therapies and immunotherapies. Some FDA-approved renal cell carcinoma drugs are A<strong>FINITOR (everolimus), AVASTIN (bevacizumab), BAVENCIO (avelumab), WELIREG (belzutifan)<\/strong>, and others.<\/p>\n\n\n\n<p>Key oncolytic virus manufacturers are working toward the development of potential therapies for renal cell carcinoma to fulfill the unmet medical needs of the currently used therapeutics. The promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/renal-cell-carcinoma-pipeline-insight\">emerging renal cell carcinoma oncolytic virus therapies<\/a> include <strong>GeneMedicine\u2019s GM 103<\/strong> (Phase I\/II) and <strong>SillaJen\u2019s PEXA-VEC<\/strong> (Phase II).&nbsp; The predicted launch of these oncolytic virus therapies will give a boost to the renal cell carcinoma market in the future.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hepatocellular-carcinoma\"><span class=\"ez-toc-section\" id=\"Hepatocellular_Carcinoma\"><\/span><strong>Hepatocellular Carcinoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Hepatocellular carcinoma occurs in <strong>~85%<\/strong> of patients diagnosed with cirrhosis. HCC is now the fifth most common cause of cancer worldwide. Five-year survival of HCC is <strong>18%<\/strong> and second to pancreatic cancer. As per DelveInsight\u2019s analysis, <strong>41,200<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatocellular-carcinoma-market\">incident cases of HCC<\/a> were observed in 2023 in the US.<\/p>\n\n\n\n<p>Current therapies mainly target angiogenesis using multikinase, VEGF, TKIs, and the tumor microenvironment with immune checkpoint inhibitors. Although many clinicians consider <strong>TECENTRIQ (atezolizumab) + AVASTIN (bevacizumab)<\/strong> as the first-line standard of care, patient-specific factors might lead to the selection of other first-line options like <strong>NEXAVAR (sorafenib), LENVIMA (lenvatinib), or IMFINZI (durvalumab) + IMJUDO (tremelimumab)<\/strong>. With various choices available in both first and second-line settings, including TKIs or immunotherapy, the best sequence for administering these therapies remains uncertain.<\/p>\n\n\n\n<p>Pharmaceutical companies are working toward the development of <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatocellular-carcinoma-pipeline-insight\">potential hepatocellular carcinoma oncolytic virus therapies<\/a> to fulfill the unmet medical needs of the currently used therapeutics. The key hepatocellular carcinoma oncolytic virus therapies in the development pipeline include <strong>Oncolys Biopharma\u2019s OBP-301<\/strong> (Phase I), <strong>Replimune\u2019s RP3<\/strong> (Phase II), and <strong>Virogin Biotech\u2019s VG161<\/strong> (Phase II).<\/p>\n\n\n\n<p>The introduction of a hepatocellular carcinoma oncolytic virus therapies approach promises to enhance treatment efficacy and reduce side effects, offering new hope for patients with this challenging liver cancer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-gastric-cancer\"><span class=\"ez-toc-section\" id=\"Gastric_Cancer\"><\/span><strong>Gastric Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Gastric cancer is the sixth most common cancer worldwide and is also the third leading cause of cancer deaths. The five-year survival rate is relatively good only in Japan, where it reaches <strong>90%<\/strong>. Among the 7MM, Japan had the highest number of <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-market\">incident cases of gastric cancer<\/a> in 2022, i.e., <strong>126K<\/strong>. Although the incidence of gastric cancer is decreasing in Western countries including the US, there is an increasing incidence of gastroesophageal junction (GEJ) cancer.<\/p>\n\n\n\n<p>The treatment of gastric cancer involves a combination of methods tailored to the cancer&#8217;s stage and location. Several approved drugs for gastric cancer include <strong>ENHERTU <\/strong>(AstraZeneca\/Daiichi Sankyo), <strong>CYRAMZA <\/strong>(Eli Lilly), <strong>OPDIVO <\/strong>(Bristol-Myers Squibb), <strong>KEYTRUDA <\/strong>(Merck), <strong>AYVAKIT <\/strong>(Blueprint Medicines), <strong>HERCEPTIN <\/strong>(Genentech), and others.<\/p>\n\n\n\n<p>At present, there are a decent number of <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-pipeline-insight\">gastric cancer oncolytic virus therapies<\/a> under investigation to improve the treatment space. The oncolytic virus therapies in the pipeline include <strong>Oncolys Biopharma\u2019s OBP-301<\/strong> (Phase II), <strong>Beijing Bio-Targeting Therapeutics Technology Co., Ltd\u2019s BioTTT001<\/strong> (Phase II), and <strong>Virogin Biotech\u2019s VG161<\/strong> (Phase I\/II). The anticipated launch of these gastric cancer oncolytic virus therapies will give a boost to the overall market growth in the future.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-soft-tissue-sarcoma\"><span class=\"ez-toc-section\" id=\"Soft_Tissue_Sarcoma\"><\/span><strong>Soft Tissue Sarcoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Soft tissue sarcoma is a rare entity, and it accounts for <strong>~1%<\/strong> of all cancer incidence in the US and represents <strong>~2% <\/strong>of cancer-related deaths. According to the DelveIsnight assessment, the US contributed the <a href=\"https:\/\/www.delveinsight.com\/report-store\/soft-tissue-sarcoma-market\">highest number of STS cases<\/a> among the 7MM.&nbsp;<\/p>\n\n\n\n<p>Currently, surgery is the only potential cure for many patients with STS, but the cancer often comes back within five years. Some of the approved drugs for soft tissue sarcoma include <strong>VOTRIENT (pazopanib)<\/strong> by GlaxoSmithKline, <strong>TECENTRIQ (atezolizumab)<\/strong> by Genentech, <strong>AYVAKIT (avapritinib)<\/strong> by Blueprint Medicines, and <strong>TAZVERIK (tazemetostat)<\/strong> by Ipsen.&nbsp;<\/p>\n\n\n\n<p>With the rise in cases, there is a high demand for novel therapies for soft tissue sarcoma, but there is only one company is working in the soft tissue sarcoma oncolytic virus therapy segment. <strong>BioInvent International<\/strong> in collaboration with <strong>Transgene <\/strong>is evaluating their drug candidate <strong>BT 001<\/strong> in the Phase I\/II <a href=\"https:\/\/www.delveinsight.com\/report-store\/soft-tissue-sarcoma-pipeline-insight\">soft tissue sarcoma oncolytic virus clinical trials<\/a>. The emergence of this soft tissue sarcoma oncolytic virus therapy will add to the market growth in the future. In addition, persistently rising cases of STS in the forecast period will help increase the STS treatment market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bone-cancer\"><span class=\"ez-toc-section\" id=\"Bone_Cancer\"><\/span><strong>Bone Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Bone sarcoma is a rare and aggressive cancer that originates in bone tissue. The chances of being diagnosed with primary bone sarcoma and the outlook for recovery vary based on individual factors. In 2023, it is anticipated that ~<strong>4,000<\/strong> people in the United States <a href=\"https:\/\/www.delveinsight.com\/blog\/bone-sarcoma-types-and-treatment\">diagnosed with primary bone sarcoma<\/a>, including <strong>2,000<\/strong> males and<strong> 1,800<\/strong> females.<\/p>\n\n\n\n<p>Treatment options often involve a combination of surgery, chemotherapy, and radiation therapy. Several drugs have been approved for managing bone cancer, including <strong>methotrexate, doxorubicin, and ifosfamide<\/strong>, which are often used in chemotherapy regimens. Additionally, targeted therapies and novel agents like <strong>denosumab and trabectedin<\/strong> are being explored to improve outcomes and reduce side effects. Despite advances in treatment, bone cancer remains a challenging condition requiring a multidisciplinary approach for effective management.<\/p>\n\n\n\n<p>Currently,<strong> Surv BioPharma Inc.<\/strong> is evaluating its lead bone cancer oncolytic virus therapy <strong>Surv.m-CRA-1<\/strong> in the Phase II stage of development. With the expected launch of this bone cancer oncolytic virus therapy, the market will witness an upsurge in growth in the coming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Oncolytic virus therapy represents a promising and evolving field in cancer treatment with the potential to address a wide range of indications. These indications include solid tumors such as melanoma, brain cancer, and pancreatic cancer, as well as breast cancer, lung cancer, bone cancer, head and neck cancer, and others. The success of oncolytic virus therapy in these contexts is attributed to its ability to specifically infect and lyse cancer cells, stimulate anti-tumor immune responses, and overcome conventional treatment limitations.&nbsp;<\/p>\n\n\n\n<p>Many pharma companies such as <strong>Akamis Bio, Amgen, AmunBio, Apices Soluciones, Beijing Bio-Targeting Therapeutics Technology Co., Ltd, BioEclipse Therapeutics, BioInvent International, BullFrog AI, Calidi Biotherapeutics, Candel Therapeutics, CG Oncology, Codagenix, Daiichi Sankyo Company, DNAtrix, EpicentRx, Genelux Corporation, GeneMedicine, Hangzhou Converd Co., Ltd., Immvira Pharma, Imugene, Istari Oncology, Lokon Pharma, Memgen, Mustang Bio, Nouscom, Oncolys Biopharma, Oncolytics Biotech, ORCA Therapeutics, Oryx GmbH, PrimeVax Immuno-Oncology, Replimune, Shanghai Sunway Biotech, Shanghai Yuansong Biotechnology, Shanghai Yunying Medical Technology, SillaJen, Sorrento Therapeutics, Surv BioPharma Inc., Takara Bio, Theolytics, Theriva Biologics, TILT Biotherapeutics, Transgene, Treovir, VacV Biotheraputics, Valo Therapeutics, Vaxiion Therapeutics, Virogin Biotech, Vyriad<\/strong>, and other are currently working with their lead assets to treat several cancers.<\/p>\n\n\n\n<p>With the involvement of these companies along with the rise in healthcare spending across the globe will propel the oncolytic virus therapy market growth. According to DelveInsight\u2019s estimates, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-cancer-therapy-market\">total oncolytic virus therapy market size<\/a> in the 7MM is projected to grow at a <strong>CAGR of 33.3%<\/strong> during the study period (2020\u20132034)<\/p>\n\n\n\n<p>Furthermore, as research progresses, the identification of additional indications and the refinement of therapeutic strategies will likely expand the <a href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-virus-cancer-therapy\">applicability of oncolytic virus therapy<\/a>, offering new hope to patients with a variety of challenging malignancies. Ultimately, this approach holds promise for significantly improving outcomes and advancing personalized cancer treatment.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-cancer-therapy-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/05173012\/Oncolytic-Virus-Market-Outlook--1024x194.png\" alt=\"Oncolytic-Virus-Market-Outlook\" class=\"wp-image-28607\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/05173012\/Oncolytic-Virus-Market-Outlook--1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/05173012\/Oncolytic-Virus-Market-Outlook--300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/05173012\/Oncolytic-Virus-Market-Outlook--150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/05173012\/Oncolytic-Virus-Market-Outlook--768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/05173012\/Oncolytic-Virus-Market-Outlook--1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/05173012\/Oncolytic-Virus-Market-Outlook--1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/05173012\/Oncolytic-Virus-Market-Outlook-.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>As cancer continues to be a leading cause of mortality worldwide, there is a growing urgency to develop innovative oncolytic virus therapies that can effectively target and eradicate cancer cells. With its unique ability to selectively infect and replicate within tumor cells, oncolytic virus therapy has emerged as a promising avenue in cancer treatment. Key [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":28971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22215,22214,22186,22183,22187,19828,22185,22182,1977,22216,22184],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-28964","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-delytact","tag-imlygic","tag-oncolytic-virus-cancer-therapy","tag-oncolytic-virus-clinical-trials","tag-oncolytic-virus-market","tag-oncolytic-virus-therapies","tag-oncolytic-virus-therapy","tag-oncolytic-virus-treatment","tag-oncolytic-viruses","tag-oncorine","tag-types-of-oncolytic-viruses","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Top 15 Indications for Oncolytic Virus Therapy<\/title>\n<meta name=\"description\" content=\"Oncolytic virus therapy represents promising and evolving field in cancer treatment with the potential to address wide range of indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Top 15 Indications for Oncolytic Virus Therapy\" \/>\n<meta property=\"og:description\" content=\"Oncolytic virus therapy represents promising and evolving field in cancer treatment with the potential to address wide range of indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-31T13:06:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-01T05:16:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/31183535\/top-15-indications-for-oncolytic-virus-therapy.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"20 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Top 15 Indications for Oncolytic Virus Therapy","description":"Oncolytic virus therapy represents promising and evolving field in cancer treatment with the potential to address wide range of indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy","og_locale":"en_US","og_type":"article","og_title":"Top 15 Indications for Oncolytic Virus Therapy","og_description":"Oncolytic virus therapy represents promising and evolving field in cancer treatment with the potential to address wide range of indications.","og_url":"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-07-31T13:06:21+00:00","article_modified_time":"2024-08-01T05:16:02+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/31183535\/top-15-indications-for-oncolytic-virus-therapy.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"20 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy","url":"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy","name":"Top 15 Indications for Oncolytic Virus Therapy","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/31183535\/top-15-indications-for-oncolytic-virus-therapy.jpg","datePublished":"2024-07-31T13:06:21+00:00","dateModified":"2024-08-01T05:16:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Oncolytic virus therapy represents promising and evolving field in cancer treatment with the potential to address wide range of indications.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/top-15-indications-for-oncolytic-virus-therapy#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/31183535\/top-15-indications-for-oncolytic-virus-therapy.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/31183535\/top-15-indications-for-oncolytic-virus-therapy.jpg","width":466,"height":284,"caption":"top-15-indications-for-oncolytic-virus-therapy"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/31183535\/top-15-indications-for-oncolytic-virus-therapy-300x183.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DELYTACT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IMLYGIC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncolytic Virus Cancer Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncolytic Virus clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncolytic virus market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">oncolytic virus therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncolytic virus therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncolytic virus treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncolytic viruses<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncorine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Types of oncolytic viruses<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DELYTACT<\/span>","<span class=\"advgb-post-tax-term\">IMLYGIC<\/span>","<span class=\"advgb-post-tax-term\">Oncolytic Virus Cancer Therapy<\/span>","<span class=\"advgb-post-tax-term\">Oncolytic Virus clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Oncolytic virus market<\/span>","<span class=\"advgb-post-tax-term\">oncolytic virus therapies<\/span>","<span class=\"advgb-post-tax-term\">Oncolytic virus therapy<\/span>","<span class=\"advgb-post-tax-term\">Oncolytic virus treatment<\/span>","<span class=\"advgb-post-tax-term\">Oncolytic viruses<\/span>","<span class=\"advgb-post-tax-term\">Oncorine<\/span>","<span class=\"advgb-post-tax-term\">Types of oncolytic viruses<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jul 31, 2024","modified":"Updated on Aug 1, 2024"},"absolute_dates_time":{"created":"Posted on Jul 31, 2024 6:36 pm","modified":"Updated on Aug 1, 2024 10:46 am"},"featured_img_caption":"top-15-indications-for-oncolytic-virus-therapy","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28964"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28964\/revisions"}],"predecessor-version":[{"id":28982,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28964\/revisions\/28982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28971"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28964"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28964"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}